Get Permission Guru, Ghosh, Chauhan, and Routray: Using indocyanine green and methylene blue for axillary reverse mapping in modified radical mastectomy for breast cancer


Introduction

The advancement of novel indicators for oncogene activity demonstrated potential in informing treatment approaches for breast cancer. The status of axillary lymph nodes plays a pivotal role in determining treatment strategies and remains a key prognostic indicator for patient outcomes.1 Currently, axillary lymph node dissection (ALND) is the standard treatment for patients with metastatic axillary lymph nodes. However, ALND is associated with significant complications, including upper extremity lymphedema (ranging from 7% to 77%)[Figure 1, Figure 2], arm/shoulder dysfunction, paresthesia, and discomfort.2 For patients with clinically node-negative axilla, sentinel lymph node biopsy (SLNB) is recommended, which significantly reduces complications compared to ALND. Despite this, SLNB alone has been shown to cause lymphedema in 7% of cases.3

In 2007, Thompson first described axillary reverse mapping (ARM), also referred to as SPLIT mapping or dual mapping technique, to identify the lymph nodes (termed ARM nodes) and lymphatic vessels of the upper limb that traverse the axillary region during axillary surgery in breast cancer patients.4 This technique involves injecting a tracer into the upper arm just before surgery to identify the ARM nodes, which is similar to the process used for the sentinel lymph node (SLN) that drains the tumor. The primary objective of ARM is to reduce the occurrence of arm lymphedema by identifying and preserving an alternative lymphatic pathway from the arm.

During ALND or SLNB, the ARM procedure can be utilized to decrease the incidence of upper extremity lymphedema by maintaining the lymphatic drainage of the arm. ARM has been performed using three visualization methods: radioisotopes, fluorescence dye, and blue dye. The most commonly used method is blue dye, while the use of fluorescent indocyanine green (ICG) dye has been reported in only five studies.5, 6, 7, 8, 9 In this study, we will evaluate the effect of the combined use of blue dye and ICG during modified radical mastectomy (MRM) in breast cancer patients.

Aim of the study was to evaluate the impact of using a combination of fluorescence dye and methylene blue during axillary reverse mapping (ARM) and to assess the feasibility of implementing ARM in breast cancer patients undergoing modified radical mastectomy (MRM).

Figure 1

Development of lymphedema

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/bfb17243-3d30-41c0-872b-cc777fb2f367image1.jpeg
Figure 2

Clinical features of lymphedema

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/bfb17243-3d30-41c0-872b-cc777fb2f367image2.jpeg

Clinico-pathological characteristics of patients

The clinico-pathological profile of the patients selected in both the groups are shown in the following Table 1.

Table 1

Clinico-pathological characteristics of patients taken in the study

Characteristics

Methylene blue

Methylene blue + ICG

Median age

58 (43-68)

52 (40-70)

Her 2: Negative

14

16

Her 2 Positive

10

8

Histological type: Invasive ductal

12

15

Invasive lobular

8

6

Mix (ductal + lobular)

4

3

ER: Positive

15

13

Negative

9

11

PR: Positive

17

12

Negative

7

12

Clinical T stage: T1

10

11

T2

10

12

T3

2

1

Clinical N stage: N0

12

16

N1

10

7

N2

1

1

N3

1

0

Review Literature

The study included 48 patients, divided equally into two groups: the Control group (24 patients) received only methylene blue, while the Experimental group (24 patients) received a combination of indocyanine green (ICG) and methylene blue. This cohort study was conducted from January 2022 to March 2023, enrolling a total of 48 patients who underwent modified radical mastectomy (MRM). These patients were diagnosed with primary breast cancer at clinical stages I-IV (Tis-T3, N0-N3, and M0) at VIMSAR, Burla. Patients were excluded if they had received preoperative radiotherapy or chemotherapy, had bilateral disease, were allergic to methylene blue or indocyanine green (ICG) dye, or had previously undergone axillary dissection. The median age of the study cohort was 55 years, ranging from 40 to 70 years. Informed consent was obtained from each patient prior to surgery.

For the Control group, 2 mL of methylene blue mixed with 2 mL of normal saline (NS) was injected subcutaneously into the upper inner arm, 4-5 cm from the axillary crease. After injection, the arm was raised for 10 minutes following a 5–6-minute massage of the injection site. In the Experimental group, 2 mL of methylene blue and 5 mg of ICG were injected using the same method[Figure 3]. This injection site was chosen to ensure any permanent tattooing caused by the dye would remain hidden.

The dye was injected prior to dissecting the clavipectoral fascia, either in a single prick or multi-prick fashion. In overlay mode, the procedure aimed to detect any dye leakage. The absence of leakage indicated that no upper limb lymphatics were injured during the procedure.

Figure 3

Site of dye injection

https://s3-us-west-2.amazonaws.com/typeset-prod-media-server/bfb17243-3d30-41c0-872b-cc777fb2f367image3.jpeg

Axillary lymph node dissection

Based on imaging assessment indicating enlargement of axillary lymph nodes, primary axillary lymph node dissection (ALND) was deemed necessary. During the procedure, axillary reverse mapping (ARM) nodes labeled with methylene blue were visible to the naked eye, while those labeled with indocyanine green (ICG) were visualized using a fluorescence imaging camera. The metastasis rates of ARM nodes and the identification rates of ARM nodes were subsequently evaluated intraoperatively. During the surgery, ARM nodes were initially detected and extracted individually, followed by subsequent examination through pathological tests.5

Pathological examination

Following the revised TNM staging system outlined in the NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 1.2016), all patients underwent evaluation for postoperative TNM staging and molecular profiling. They were categorized into luminal A, luminal B, basal, or overexpressed HER2 types based on molecular profiling, as well as assessed for estrogen/progesterone receptor (ER/PR) status and HER2/neu status.

Statistical analysis

According to the updated TNM staging system delineated in the NCCN Clinical Practice Guidelines in Oncology: Breast Cancer (Version 1.2016),10 all individuals underwent assessment for postoperative TNM staging and molecular profiling. They were stratified into luminal A, luminal B, basal, or HER2 overexpression subtypes based on molecular profiling, alongside evaluation of estrogen/progesterone receptor (ER/PR) status and HER2/neu expression.

Results

Dyeing rate

The rate of successful dyeing for ARM nodes overall was 83.33% (40 out of 48). Significant differences were noted in the clinical stages of N0-N1 and N3-N4 between the group receiving methylene blue alone and the group receiving both methylene blue and indocyanine green[Table 2].

Table 2

visualisation rate of the two groups

Parameters

Methylene blue group

Combination group (MB + ICG)

Total patients

24

24

Visualization

18/24 (75%)

23/24 (95.8%)

Lymph node

23 (95.84%): N0-N1 1 (4.17%): N2-N3

22 (91.67%): N0-N1 2 (8.34%): N2-N3

Postoperative limb circumference

There was a somewhat lower difference in limb circumference in the Control group compared to the Experimental group from day 1 to day 6. By day 7 and 8, the difference in limb circumference between both groups tended to stabilize. There was no significant disparity noted in the duration of hospital stay between patients in these two groups (P > 0.05)[Table 3].

Table 3

Post-operative limb circumference during the 8 days of follow up

Days

Methylene blue (24)

Methylene blue + ICG (24)

t

P

D1

2.23 ± 0.745

2.421 ± 1.131

0.805

0.312

D2

2.49 ± 0.781

2.83 ± 1.72

1.040

0.310

D3

2.58 ± 1.101

3.159 ± 2.412

1.012

0.355

D4

2.476 ± 1.150

2.910 ± 2.390

0.786

0.501

D5

2.410 ± 1.11

2.701 ± 2.511

0.442

0.672

D6

2.380 ± 1.085

2.396 ± 2.55

0.131

0.912

D7

2.317 ± 1.102

2.436 ± 2.444

0.44

0.89

D8

2.054 ± 0.939

2.010 ± 2.221

0.059

0.913

Total days

11.765 ± 3.152

11.432 ± 3.560

0.41

0.691

Postoperative injection site induration

Observations were made regarding the diameter of induration, which represents the blue tattooing effect at the injection site. There was a tendency for a larger difference in induration diameter among patients in the Control group compared to those in the Experimental group. However, statistically significant differences (P < 0.05) were only observed from day 3 to day 8[Table 4].

Table 4

Post-operative injection site induration during the 8 days of follow up

Days

Methylene blue + ICG (24)

Methylene blue (24)

t

P

D1

2.609 ± 0.467

2.427 ± 0.504

1.28

0.201

D2

2.793 ± 0.466

2.520 ± 0.499

1.609

0.15

D3

2.756 ± 0.563

2.575 ± 0.410

2.202

0.039

D4

2.856 ± 0.458

2.531 ± 0.356

2.492

0.020

D5

2.9 ± 0.489

2.35 ± 0.316

2.635

0.013

D6

2.771 ± 0.519

2.374 ± 0.346

2.593

0.020

D7

2.8 ± 0.480

2.408 ± 0.396

2.338

0.017

D8

2.504 ± 0.521

2.300± 0.407

2.219

0.044

Positive lymph node

The incidence of lymph node positivity was higher in the group receiving both Methylene blue and ICG, while it remained inconclusive in the group receiving Methylene blue alone[Table 5].

Table 5

Rate of positive lymph node

Groups

Lymph node positive

Lymph node negative

Methylene blue + ICG (24)

14 (58.34%)

10 (41.67%)

Methylene blue (24)

12 (50%)

12 (50%)

Discussion

Indocyanin green (ICG) also known as Tricarbocyanine dye emits light after excitation under infrared light at 806 nm. ICG is highly soluble in water. It binds to beta-lipoproteins, particularly albumin. Since lymph nodes also have high protein content, ICG accumulates in lymph nodes and when near infrared light is illuminated, ICG gets excited and emits green light.8, 11 The optimal concentration of ICG is 3-6 micro gram per mL. ICG dyed lymph node becomes visible 5 minutes after light excitation and remains visible uptup till minutes (1 hour). The transit time of ICG is very less compared to Methylene blue. Elimination of ICG occurs through liver and intra-vascular half-life is 3-4 minutes. Side effects include allergic reactions, skin damage, sub cutaneous nodules and permanent tattooing. The 10% rule of sentinel node states that all nodes with radioactive count of 10% or more of the hottest node ex-vivo should be removed.9, 12, 13

Methylene blue, also known as Methylthionium chloride (derivative of Phenothiazine) which is a monoamine oxidase inhibitor, is a dark green color powder that yeilds blue solution in water. The peak light absorption occurs around 670 nm. Side effects include headache, confusion, vomiting, shortness of breath, Serotonin syndrome, and allergic reactions. It also causes urine, sweat, and stool to turn blue to green in color. However, it is cheap, needs simple pre-operative preparation and is non-radioactive. 14, 15

The underlying principle of the ARM technique posits that the lymphatics of the upper extremity are typically not implicated in the metastasis of primary breast tumors. Therefore, identifying and preserving these lymphatics is believed to reduce the risk of lymphedema.6 However, certain studies suggest that the incidence of metastatic tumors in ARM nodes ranges from 14% to 43%. Currently, most research on the ARM technique focuses on its feasibility and aims to reduce lymphedema incidence by preserving ARM nodes/lymphatics, with less emphasis on safety considerations.16, 17, 18 In this study, our objective is to enhance the ARM procedure by utilizing a combination of ICG and methylene blue dye while prioritizing safety, feasibility, and enhancing the identification rate of ARM nodes.

Summary

The rate of ARM node identification reached 93.18%. In the Experimental group, visualizing ARM nodes was notably higher [23 out of 24 (95.8%)] compared to the Control group [18 out of 24 (75%)]. This study indicates that the combined use of methylene blue and ICG enhances ARM node identification, especially beneficial for patients with more advanced breast cancer.19

There were no significant differences observed in limb circumference between the Experimental and Control groups. However, the diameter of induration at the injection site was notably larger in the Experimental group compared to the Control group.

Conclusion

The identification rate of ARM nodes using the combination of methylene blue and ICG is significantly higher compared to methylene blue alone. This finding suggests that the combined approach could serve as a valuable tool for surgical therapy in patients with invasive breast cancer.

Study Limitations

Our study was limited by its small sample size, potentially hindering our ability to detect significant differences in lymphedema incidence between the groups. Large-scale studies are highly recommended to confirm these findings. Additionally, the short-term follow-up of 6 months may not have provided sufficient time to distinguish transient lymphedema caused by acute surgical edema from permanent lymphedema. Therefore, longer follow-up periods are warranted for a more comprehensive evaluation.

Source of Funding

None.

Conflict of Interest

None.

References

1 

AH Narasannaiah AZ Anwar KV Manjunath R Yeshwanth S Althaf S Althaf Reverse axillary mapping in breast cancer using blue dye: a tertiary setup experienceCureus202113101857610.7759/cureus.18576

2 

MA Beek PD Gobardhan EJ Schoenmaeckers EG Klompenhouwer HJT Rutten AC Voogd Axillary reverse mapping in axillary surgery for breast cancer: an update of the current statusBreast Cancer Res Treat2016158342132

3 

GH Lyman MR Somerfield LD Bosserman CL Perkins DL Weaver AE Giuliano Sentinel lymph node biopsy for patients with early-stage breast cancerJ Clin Oncol20173555614

4 

WJ Gradishar BO Anderson R Balassanian SL Blair HJ Burstein A Cyr Breast Cancer Version 2.2015J Natl Compr Canc Netw201513444875

5 

D Pavlista L Dostalek Z Velenska Axillary Reverse Mapping in Breast Cancer Surgery - Functional StudyNeoplasma20226924259

6 

M Thompson S Korourian R Henry-Tillman L Adkins S Mumford KC Westbroo Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservationAnn Surg Oncol200714618905

7 

C Nos B Lesieur KB Clough F Lecuru Blue dye injection in the arm to conserve the lymphatic drainage of the arm in breast cancer patients requiring an axillary dissectionAnn Surg Oncol200714924906

8 

KS Kumar GN Hemanth PK Panjwani S Manjunath RS Ramesh R Burrah Feasibility of axillary reverse mapping and clinicopathological features predicting ARM node metastasis in breast cancer-a pilot studyIndian J Surg Oncol20178211922

9 

PD Gobardhan EG Klompenhouwer MA Beek AC Voogd EJ Luiten Axillary reverse mapping: preserving nodes during an axillary lymph node dissectionNed Tijdschr Geneeskd2013157225646

10 

National Comprehensive Cancer Network, NCCN. (2017). "Breast Cancer, version 32017

11 

AS Ibrahim HM Khaled NNH Mikhail H Baraka H Kamel Cancer incidence in egypt: results of the national population-based cancer registry programJ Cancer Epidemiol201443797110.1155/2014/437971

12 

U Kuusk N Seyednejad EC Mckevitt CK Dingee SM Wiseman Axillary reverse mapping in breast cancer: A Canadian experienceJ Surg Oncol201411077915

13 

J Ferlay I Soerjomataram R Dikshit S Eser C Mathers M Rebelo Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012Int J Cancer2015136535986

14 

VS Klimberg A new concept toward the prevention of lymphoedema: axillary reverse mappingJ Surg Oncol20089775634

15 

MA Beek PD Gobardhan EJ Schoenmaeckers Axillary reverse mapping in axillary surgery for breast cancer: An update of the current statusBreast Cancer Res Treat2016158342132

16 

TF Hack L Cohen J Katz LS Robson P Goss Physical and psychological morbidity after axillary lymph node dissection for breast cancerJ Clin Oncol19991711439

17 

T Yue D Zhuang P Zhou L Zheng i Fan J Zhu A prospective study to assess the feasibility of axillary reverse mapping and evaluate its effect on preventing lymphedema in breast cancer patientsClin Breast Cancer20151543016

18 

JW Han YJ Seo JE Choi SH Kang YK Bae SJ Le The efficacy of arm node preserving surgery using axillary reverse mapping for preventing lymphedema in patients with breast cancerJ Breast Cancer2012151917

19 

C Connor M Mcginness J Mammen Axillary reverse mapping: a prospective study in women with clinically node-negative and node-positive breast cancerAnn Surg Oncol201320103303710.1245/s10434-013-3113-4



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

  • Article highlights
  • Article tables
  • Article images

Article History

Received : 09-06-2024

Accepted : 20-07-2024


View Article

PDF File   Full Text Article


Copyright permission

Get article permission for commercial use

Downlaod

PDF File   XML File   ePub File


Digital Object Identifier (DOI)

Article DOI

https://doi.org/10.18231/j.jdpo.2024.018


Article Metrics






Article Access statistics

Viewed: 201

PDF Downloaded: 49



Medical Abbreviation List